People with MS on rituximab had more hospital stays

Credibility

Interest

Share:1 min read

Key Takeaway

People with MS taking rituximab had more hospital stays and more low levels of infection-fighting proteins than those taking Ocrevus.

What They Found

Researchers compared health records of people with MS taking ocrelizumab (Ocrevus) or rituximab. At one medical center, hospital stays were more common among people taking rituximab. The same pattern appeared in records from other medical centers. Low levels of infection-fighting proteins were also more common with rituximab in both groups. The abstract does not report whether infection rates differed between the drugs.

Who Should Care and Why

This study included people with MS treated at University of California medical centers. It compared two drugs used in MS care: Ocrevus and rituximab. Hospital stays were the main outcome researchers tracked. They also tracked low levels of infection-fighting proteins. The findings describe differences between these treatment groups, not proof that either drug caused those differences.

Important Considerations

Researchers looked back at health records for 813 people at one center and 648 people at other centers. Because people were not randomly assigned a drug, other differences between groups may have affected the results. You cannot tell from this abstract whether either drug led to more infections.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News